High density lipoprotein biochemistry

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

High density lipoprotein biochemistry On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of High density lipoprotein biochemistry

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on High density lipoprotein biochemistry

CDC on High density lipoprotein biochemistry

High density lipoprotein biochemistry in the news

Blogs on High density lipoprotein biochemistry

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for High density lipoprotein biochemistry

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]

Pathophysiology

Structure and Function

  • HDL are the smallest of the lipoproteins. They are the densest because they contain the highest proportion of protein. They contain the A class of apolipoproteins.
  • The liver synthesizes these lipoproteins as complexes of apolipoproteins and phospholipid, which resemble cholesterol-free flattened spherical lipoprotein particles. They are capable of picking up cholesterol, carried internally, from cells they interact with.
  • A plasma enzyme called lecithin-cholesterol acyltransferase (LCAT) converts the free cholesterol into cholesteryl ester (a more hydrophobic form of cholesterol) which is then sequestered into the core of the lipoprotein particle eventually making the newly synthesized HDL spherical. They increase in size as they circulate through the bloodstream and incorporate more cholesterol molecules into their structure.
  • Thus it is the concentration of large HDL particles which more accurately reflects protective action, as opposed to the concentration of total HDL particles.[1] This ratio of large HDL to total HDL particles varies widely and is only measured by more sophisticated lipoprotein assays using either electrophoresis (the original method developed in the 1970s), or newer NMR spectroscopy, NMR spectroscopy methods, developed in the 1990s.
  • HDL particles are not inherently protective. It is only the HDL particles which become the largest (actually picking up and carrying cholesterol) which are protective. There is no reliable relationship between total HDL and large HDL, and more sophisticated analyses which actually measure large HDL, not just total, correlate much better with clinical outcomes [2].

HDL Subfractions

Based on Physicochemical Properties
  • HDL 2 density is from the Apo A-I HDL particles, whereas HDL 3 density is from Apo A-I and Apo A-II.
  • Many studies have postulated an association between cholesterol efflux from peripheral tissue, and Apo A-I HDL particles, whereas the HDL 3 containing both Apo AI and A-II are less effective [3] [4].
  • Moreover, the Apo A-II are known to disturb the metabolism of large VLDL and encourage visceral fat accumulation.
Based on NMR (Nuclear Magnetic Ray) Spectroscopy

HDL Metabolism

  • As mentioned above, the HDL is synthesized in liver and intestines as small nascent particles, composed mainly of phospholipids and apolipoproteins.
  • As it travels in the blood it acquires surface components, like more phospholipids, cholesterol and apolipoproteins, from triglyceride depleted chylomicrons and remnants of VLDL.
  • As this initial HDL particle contains less amounts of cholesterol, it acquires free unesterified cholesterol from tissues like liver and arterial wall. This hydrophobic free cholesterol sinks into the center of the HDL particle. The Apolipoprotein A1 acts as a signal protein in mobilizing cholesterol esters from within the cells.
  • In the peripheral tissues, the nascent HDL particles interact with a cell surface protein called ABCA1 (also known as cholesterol efflux regulatory protein, CERP). High cholesterol levels induce expression of ABCA1 gene and production of the protein. Mutations of this transport protein gene causes familial HDL deficiencies and Tangier disease. The HDL also accepts cholesterol from triglycerides that has undergone lipolysis.
  • Once the cholesterol is acquired by the nascent HDL particles from the peripheral tissues, it gets esterified by a plasma enzyme LCAT (Lecithin-cholesterol acyltransferase). This enzyme is activated by apolipoprotein A1 .

Cholesterol Ester Transfer Protein (CETP)

  • This protein mediates exchange of cholesterol between HDL particles, and triglyceride rich LDL and VLDL in both directions.
  • It is normally present in both periphery and liver and functions to channel cholesterol to the liver for uptake and metabolism.

HDL Cholesterol and Its Role in Inflammation

In the stress response, serum amyloid A, which is one of the acute phase proteins and an apolipoprotein, is under the stimulation of cytokines (IL-1, IL-6) and cortisol produced in the adrenal cortex and carried to the damaged tissue incorporated into HDL particles. At the inflammation site, it attracts and activates leukocytes. In chronic inflammations, its deposition in the tissues manifests itself as amyloidosis.

Historically, beginning in the late 1970's cholesterol and lipid assays were promoted to estimate total HDL-cholesterol because such tests used to be far less expensive, by about 50 fold, than measured lipoprotein particle concentrations and subclass analysis. Over time, with continued research, decreasing costs, greater availability and wider acceptance of other "lipoprotein subclass analysis" assay methods, including NMR spectroscopy, human studies have continued to show a stronger correlation between human clinically obvious cardiovascular events and quantitatively measured large HDL-particle concentrations [5].

Recommended Range

The American Heart Association, NIH and NCEP provides a set of guidelines for male fasting HDL levels and risk for heart disease.

Level mg/dL Level mmol/L Interpretation
<40 <1.03 Low HDL cholesterol, heightened risk for heart disease, <50 is the value for women
40–59 1.03–1.52 Medium HDL level
>60 >1.55 High HDL level, optimal condition considered protective against heart disease

More sophisticated laboratory methods measure not just the total HDL but also the range of HDL particles, e.g. "lipoprotein subclass analysis", typically divided into several groups by size, instead of just the total HDL concentration as listed above. The largest groups (most functional) of HDL particles have the most protective effects. The groups of smallest particles reflect HDL particles which are not actively transporting cholesterol, thus not protective.

References

  1. Kwiterovich PO. The Metabolic Pathways of High-Density Lipoprotein, Low-Density Lipoprotein, and Triglycerides: A Current Review. Am J Cardiol 2000;86(suppl):5L.
  2. Tran-Dinh A, Diallo D, Delbosc S; et al. (2013). "HDL and endothelial protection". British Journal of Pharmacology. doi:10.1111/bph.12174. PMID 23488589. Unknown parameter |month= ignored (help)
  3. Yin K, Tang SL, Yu XH; et al. (2013). "Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE-/- mice possibly via activated STAT3-mediated upregulation of tristetraprolin". Acta Pharmacologica Sinica. doi:10.1038/aps.2013.10. PMID 23564081. Unknown parameter |month= ignored (help)
  4. Mazer NA, Giulianini F, Paynter NP, Jordan P, Mora S (2013). "A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study". Clinical Chemistry. doi:10.1373/clinchem.2012.196949. PMID 23426429. Unknown parameter |month= ignored (help)
  5. Umemoto T, Han CY, Mitra P; et al. (2013). "Apolipoprotein A-I and HDL Have Anti-Inflammatory Effects onAdipocytes via Cholesterol Transporters: ATP-Binding Cassette (ABC) A-1, ABCG-1 and Scavenger Receptor B-1(SRB-1)". Circulation Research. doi:10.1161/CIRCRESAHA.111.300581. PMID 23501697. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources